Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.69 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.69 |
| ▸ | FAAH | O00519 | 7/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.51 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15650880 | 1.00 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 | |
| SCHEMBL1713087 | 1.00 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 | |
| SCHEMBL1713210 | 1.00 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 | |
| SCHEMBL17097126 | 1.00 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 | |
| SCHEMBL8019819 | 1.00 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 | |
| SCHEMBL25188341 | 1.00 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 | |
| SCHEMBL9162299 | 1.00 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 | |
| SCHEMBL8005686 | 1.00 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 | |
| SCHEMBL872338 | 1.00 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 | |
| SCHEMBL1830843 | 1.00 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087250-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2021-03-25 | — | — | US | claimed |
| EP-3006045-B3 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | CYPRUMED GMBH (AT) | 2021-03-17 | — | — | EP | claimed |
| EP-3773475-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | Cyprumed GmbH (AT) | 2021-02-17 | — | — | EP | claimed |
| WO-2019193204-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2019-10-10 | — | — | WO | claimed |
| EP-3204045-B1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-12-05 | — | — | EP | claimed |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2018-10-04 | — | — | US | claimed |
| WO-2018065634-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE NASAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-04-12 | — | — | WO | claimed |
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2017-10-26 | — | — | US | claimed |
| EP-3204045-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | Cyprumed GmbH (AT) | 2017-08-16 | — | — | EP | claimed |
| WO-2017060500-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2017-04-13 | — | — | WO | claimed |
| EP-3006045-B1 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | CYPRUMED GMBH (AT) | 2017-04-12 | — | — | EP | claimed |
| WO-2016055550-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2016-04-14 | — | — | WO | claimed |
| EP-3006045-A1 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | Cyprumed GmbH (AT) | 2016-04-13 | — | — | EP | claimed |
| US-20140056953-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | NOVO NORDISK A/S (DK) | 2014-02-27 | — | — | US | claimed |
| EP-2696847-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | Novo Nordisk A/S (DK) | 2014-02-19 | — | — | EP | claimed |
| WO-2012140155-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | NOVO NORDISK A/S (DK) | 2012-10-18 | — | — | WO | claimed |
| US-5238917-A | Drug delivery, storage stability | TEIKOKU SEIYAKU KABUSHIKI KAISHA (JP) | 1993-08-24 | — | — | US | claimed |
| EP-0418642-B1 | HIGH-ABSORBABLE TRANSVAGINAL PREPARATION CONTAINING BIOLOGICALLY ACTIVE PEPTIDES | TEIKOKU SEIYAKU KABUSHIKI KAISHA (JP) | 1993-06-09 | — | — | EP | claimed |
| EP-0418642-A1 | High-absorbable transvaginal preparation containing biologically active peptides | TEIKOKU SEIYAKU KABUSHIKI KAISHA (JP) | 1991-03-27 | — | — | EP | claimed |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | LE ROUX DANIELLE MARIE (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2026-01-29 | — | — | US | disclosed |
| EP-4658374-A1 | METHODS FOR PREPARING CRYSTALLINE PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2025-12-10 | — | — | EP | disclosed |
| US-20250367295-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SPOKE SCIENCES, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4651854-A1 | FORMULATIONS OF LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2025-11-26 | — | — | EP | disclosed |
| EP-3928776-B1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SPOKE SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4642440-A1 | COMPOSITIONS AND METHODS TO INCREASE THE SYSTEMIC BIOAVAILABILITY OF A POLYPEPTIDE THERAPEUTIC AGENT UNDERGOING ORAL ADMINISTRATION | ALGIPHARMA AS (NO) | 2025-11-05 | — | — | EP | disclosed |
| US-20250268861-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | SPOKE SCIENCES, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4563530-A1 | SPHERICAL CALCIUM CARBONATE PARTICLES | Sakai Chemical Industry Co., Ltd. (JP) | 2025-06-04 | — | — | EP | disclosed |
| US-12303487-B2 | N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions | SPOKE SCIENCES, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250120939-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SPOKE SCIENCES, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-12208118-B2 | Pharmaceutical compositions for delivery of peptide | ANYA BIOPHARM INC. (CN) | 2025-01-28 | — | — | US | disclosed |
| EP-4486366-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | Cyprumed GmbH (AT) | 2025-01-08 | — | — | EP | disclosed |
| EP-4472999-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND PHARMACEUTICAL COMPOSITIONS THEREOF | Janssen Pharmaceutica NV (BE) | 2024-12-11 | — | — | EP | disclosed |
| WO-2024163643-A1 | METHODS FOR PREPARING CRYSTALLINE PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-08 | — | — | WO | disclosed |
| US-20240261408-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SPOKE SCIENCES, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| US-20240254180-A1 | COMPOSITIONS OF PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-01 | — | — | US | disclosed |
| WO-2024155552-A1 | FORMULATIONS OF LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024141760-A1 | COMPOSITIONS AND METHODS TO INCREASE THE SYSTEMIC BIOAVAILABILITY OF A POLYPEPTIDE THERAPEUTIC AGENT UNDERGOING ORAL ADMINISTRATION | ALGIPHARMA AS (NO) | 2024-07-04 | — | — | WO | disclosed |
| US-11939361-B2 | Compositions of peptide inhibitors of Interleukin-23 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-26 | — | — | US | disclosed |
| US-20240041983-A1 | IMPROVED PHARMACEUTICAL FORMULATIONS OF GLP-1 RECEPTOR AGONISTS | CYPRUMED GMBH (AT) | 2024-02-08 | — | — | US | disclosed |
| WO-2024024651-A1 | SPHERICAL CALCIUM CARBONATE PARTICLES | 堺化学工業株式会社 | 2024-02-01 | — | — | WO | disclosed |
| US-20240009208-A1 | STABILIZATION OF CANNABINOIDS WITHIN SOLID DOSAGE FORMS | RECEPTOR HOLDINGS, INC. (US) | 2024-01-11 | — | — | US | disclosed |
| US-20240000879-A1 | HERBAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY | SPOKE SCIENCES, INC. (US) | 2024-01-04 | — | — | US | disclosed |
| EP-4247403-A1 | COMPOSITIONS OF PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN Pharmaceutica NV (BE) | 2023-09-27 | — | — | EP | disclosed |
| US-20230293479-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023166179-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2023-09-07 | — | — | WO | disclosed |
| CN-116669710-A | Compositions of peptide inhibitors of interleukin-23 receptor | 詹森药业有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2023150500-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND PHARMACEUTICAL COMPOSITIONS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | WO | disclosed |
| EP-4210680-A1 | IMPROVED PHARMACEUTICAL FORMULATIONS OF GLP-1 RECEPTOR AGONISTS | Cyprumed GmbH (AT) | 2023-07-19 | — | — | EP | disclosed |
| EP-3509573-B1 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | ANYA BIOPHARM INC (TW) | 2023-05-24 | — | — | EP | disclosed |
| US-20230075677-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2023-03-09 | — | — | US | disclosed |
| CN-110325052-B | Application of aspartic acid fatty acyl derivative in preparation of animal feed additive | 彭险峰 | 2022-11-18 | — | — | CN | disclosed |
| US-20220288111-A1 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | ANYA BIOPHARM INC. (CN) | 2022-09-15 | — | — | US | disclosed |
| US-11389474-B2 | Pharmaceutical compositions for delivery of peptide | ANYA BIOPHARM INC. (CN) | 2022-07-19 | — | — | US | disclosed |
| US-20220177532-A1 | COMPOSITIONS OF PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | PROTAGONIST THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2022109328-A1 | COMPOSITIONS OF PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-27 | — | — | WO | disclosed |
| US-20220133857-A1 | ORAL FORMULATION AND TREATMENT OF PTH ANALOG | ANYA BIOPHARM INC. (TW) | 2022-05-05 | — | — | US | disclosed |
| US-20220133685-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| WO-2022072864-A2 | STABILIZATION OF CANNABINOIDS WITHIN SOLID DOSAGE FORMS | RECEPTOR HOLDINGS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022049310-A1 | IMPROVED PHARMACEUTICAL FORMULATIONS OF GLP-1 RECEPTOR AGONISTS | CYPRUMED GMBH (AT) | 2022-03-10 | — | — | WO | disclosed |
| US-11246852-B2 | Fast-acting plant-based medicinal compounds and nutritional supplements | RECEPTOR HOLDINGS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| CN-109069475-B | Fast acting botanical pharmaceutical compounds and nutritional supplements | 受体控股公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-3928776-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | Receptor Holdings, Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20210393575-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | RECEPTOR HOLDINGS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3883595-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | Receptor Holdings, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-11129897-B2 | Fast-acting plant-based medicinal compounds and nutritional supplements | RECEPTOR HOLDINGS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| EP-3445356-B1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20210087250-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2021-03-25 | — | — | US | disclosed |
| EP-3006045-B3 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | CYPRUMED GMBH (AT) | 2021-03-17 | — | — | EP | disclosed |
| EP-3773475-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | Cyprumed GmbH (AT) | 2021-02-17 | — | — | EP | disclosed |
| US-10905744-B2 | Pharmaceutical formulations for the oral delivery of peptide drugs | CYPRUMED GMBH (AT) | 2021-02-02 | — | — | US | disclosed |
| CN-111971027-A | Oral formulations and treatments for parathyroid hormone analogs | 奥孟亚股份有限公司 | 2020-11-20 | — | — | CN | disclosed |
| WO-2020183318-A1 | ORAL FORMULATION AND TREATMENT OF PTH ANALOG. | ANYA BIOPHARM INC. (TW) | 2020-09-17 | — | — | WO | disclosed |
| US-20200268821-A1 | HERBAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY | RECEPTOR HOLDINGS, INC. (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200254041-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | RECEPTOR HOLDINGS, INC. (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3672610-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | Receptor Holdings, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-3672608-A1 | HERBAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY | Receptor Holdings, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20200197521-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| CN-111225678-A | Plant and synthetic cannabinoid formulations with rapid onset and prolonged action | 受体控股公司 | 2020-06-02 | — | — | CN | disclosed |
| CN-111163790-A | Herbal composition with improved bioavailability | 受体控股公司 | 2020-05-15 | — | — | CN | disclosed |
| US-20200121796-A1 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | ANYA BIOPHARM INC. (CN) | 2020-04-23 | — | — | US | disclosed |
| US-20200101034-A1 | RAPID AND CONTROLLED DELIVERY OF COMPOSITIONS WITH RESTORED ENTOURAGE EFFECTS | RECEPTOR HOLDINGS, INC. (US) | 2020-04-02 | — | — | US | disclosed |
| US-10588974-B2 | Fast-acting plant-based medicinal compounds and nutritional supplements | RECEPTOR HOLDINGS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20200078332-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190336472-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2019-11-07 | — | — | US | disclosed |
| WO-2019193204-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2019-10-10 | — | — | WO | disclosed |
| EP-3548018-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | Receptor Holdings, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-3509573-A1 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | Anya Biopharm Inc. (TW) | 2019-07-17 | — | — | EP | disclosed |
| US-20190117778-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR LIFE SCIENCES, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| WO-2019071211-A1 | HERBAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY | RECEPTOR LIFE SCIENCES, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019071213-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | RECEPTOR LIFE SCIENCES, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019058273-A1 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | ANYA BIOPHARM INC. (TW) | 2019-03-28 | — | — | WO | disclosed |
| EP-3204045-B1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-12-05 | — | — | EP | disclosed |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2018-10-04 | — | — | US | disclosed |
| WO-2018102029-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR LIFE SCIENCES (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018065634-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE NASAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-04-12 | — | — | WO | disclosed |
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2017-10-26 | — | — | US | disclosed |
| WO-2017185038-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR LIFE SCIENCES (US) | 2017-10-26 | — | — | WO | disclosed |
| EP-3204045-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | Cyprumed GmbH (AT) | 2017-08-16 | — | — | EP | disclosed |
| WO-2017060500-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2017-04-13 | — | — | WO | disclosed |
| EP-3006045-B1 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | CYPRUMED GMBH (AT) | 2017-04-12 | — | — | EP | disclosed |
| WO-2016055550-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2016-04-14 | — | — | WO | disclosed |
| EP-3006045-A1 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | Cyprumed GmbH (AT) | 2016-04-13 | — | — | EP | disclosed |
| US-20150273069-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | NOVO NORDISK A/S (DK) | 2015-10-01 | — | — | US | disclosed |
| US-20150250882-A1 | Fatty Acid Acylated Amino Acids for Growth Hormone Delivery | NOVO NORDISK HEALTHCARE AG (CH) | 2015-09-10 | — | — | US | disclosed |
| EP-2908845-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR GROWTH HORMONE DELIVERY | Novo Nordisk Health Care AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| EP-2908844-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | Novo Nordisk A/S (DK) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014060512-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR GROWTH HORMONE DELIVERY | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060472-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | NOVO NORDISK A/S (DK) | 2014-04-24 | — | — | WO | disclosed |
| US-20140056953-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | NOVO NORDISK A/S (DK) | 2014-02-27 | — | — | US | disclosed |
| EP-2696847-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | Novo Nordisk A/S (DK) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012140155-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | NOVO NORDISK A/S (DK) | 2012-10-18 | — | — | WO | disclosed |
| US-5238917-A | Drug delivery, storage stability | TEIKOKU SEIYAKU KABUSHIKI KAISHA (JP) | 1993-08-24 | — | — | US | disclosed |
| EP-0418642-B1 | HIGH-ABSORBABLE TRANSVAGINAL PREPARATION CONTAINING BIOLOGICALLY ACTIVE PEPTIDES | TEIKOKU SEIYAKU KABUSHIKI KAISHA (JP) | 1993-06-09 | — | — | EP | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| EP-0418642-A1 | High-absorbable transvaginal preparation containing biologically active peptides | TEIKOKU SEIYAKU KABUSHIKI KAISHA (JP) | 1991-03-27 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (34 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230075677-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | EPHX2 4247/4885NOD1 3604/4885FAAH 250/4885 |
| US-20230293479-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | GPR18, SLC1A5, CNR2 | EPHX2 2424/4885NOD1 2839/4885FAAH 11/4885 |
| US-20150273069-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | GLP1R, SLC27A1, IAPP | EPHX2 4168/4885NOD1 2091/4885FAAH 71/4885 |
| US-11939361-B2 | Compositions of peptide inhibitors of Interleukin-23 receptor | IL23R, IL1RN, IL17A | EPHX2 3425/4885NOD1 52/4885FAAH 2650/4885 |
| US-20240254180-A1 | COMPOSITIONS OF PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL17A | EPHX2 3425/4885NOD1 52/4885FAAH 2650/4885 |
| US-20240041983-A1 | IMPROVED PHARMACEUTICAL FORMULATIONS OF GLP-1 RECEPTOR AGONISTS | GLP1R, GIPR, GCGR | EPHX2 1859/4885NOD1 366/4885FAAH 502/4885 |
| US-20250268861-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | FAAH, CNR2, FABP2 | EPHX2 1872/4885NOD1 4580/4885FAAH 1/4885 |
| US-20200254041-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | FAAH, CNR1, GPR18 | EPHX2 2509/4885NOD1 2484/4885FAAH 1/4885 |
| US-11246852-B2 | Fast-acting plant-based medicinal compounds and nutritional supplements | SLC1A5, SLC43A1, SLC27A2 | EPHX2 4247/4885NOD1 3604/4885FAAH 250/4885 |
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | SLC30A5, SLC30A6, SON | EPHX2 4791/4885NOD1 4020/4885FAAH 4519/4885 |
| US-20200268821-A1 | HERBAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY | SLC7A1, SLC1A5, SLC3A2 | EPHX2 1525/4885NOD1 2680/4885FAAH 439/4885 |
| US-12303487-B2 | N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions | FAAH, CNR2, FABP2 | EPHX2 1872/4885NOD1 4580/4885FAAH 1/4885 |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | SLC30A5, SLC39A11, SLC30A6 | EPHX2 4589/4885NOD1 3431/4885FAAH 4365/4885 |
| US-20220177532-A1 | COMPOSITIONS OF PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL17A | EPHX2 3425/4885NOD1 52/4885FAAH 2650/4885 |
| US-20190336472-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | GPR18, SLC1A5, CNR2 | EPHX2 2424/4885NOD1 2839/4885FAAH 11/4885 |
| US-20240000879-A1 | HERBAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY | SLC7A1, SLC1A5, SLC3A2 | EPHX2 1525/4885NOD1 2680/4885FAAH 439/4885 |
| US-20240009208-A1 | STABILIZATION OF CANNABINOIDS WITHIN SOLID DOSAGE FORMS | DGKZ, DSP, DMPK | EPHX2 3026/4885NOD1 2999/4885FAAH 142/4885 |
| US-20210087250-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | VIP, PTMS, VASP | EPHX2 4291/4885NOD1 4555/4885FAAH 3710/4885 |
| US-20140056953-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | SLC27A1, SLC27A2, FABP2 | EPHX2 1812/4885NOD1 3906/4885FAAH 63/4885 |
| US-20200101034-A1 | RAPID AND CONTROLLED DELIVERY OF COMPOSITIONS WITH RESTORED ENTOURAGE EFFECTS | FABP2, ASS1, AADAT | EPHX2 2470/4885NOD1 4439/4885FAAH 48/4885 |
| US-20240261408-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | EPHX2 4247/4885NOD1 3604/4885FAAH 250/4885 |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | ADM2, TAS2R42, ACP1 | EPHX2 2569/4885NOD1 1861/4885FAAH 3546/4885 |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | VIP, GIPR, SLC10A2 | EPHX2 3505/4885NOD1 2707/4885FAAH 1139/4885 |
| US-20250120939-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | EPHX2 4247/4885NOD1 3604/4885FAAH 250/4885 |
| US-11129897-B2 | Fast-acting plant-based medicinal compounds and nutritional supplements | SLC1A5, SLC43A1, SLC27A2 | EPHX2 4247/4885NOD1 3604/4885FAAH 250/4885 |
| US-20190117778-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | EPHX2 4247/4885NOD1 3604/4885FAAH 250/4885 |
| US-10588974-B2 | Fast-acting plant-based medicinal compounds and nutritional supplements | SLC1A5, SLC43A1, SLC27A2 | EPHX2 4247/4885NOD1 3604/4885FAAH 250/4885 |
| US-20210393575-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | FAAH, CNR2, FABP2 | EPHX2 1872/4885NOD1 4580/4885FAAH 1/4885 |
| US-20220133685-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | EPHX2 4247/4885NOD1 3604/4885FAAH 250/4885 |
| US-20200197521-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | EPHX2 4247/4885NOD1 3604/4885FAAH 250/4885 |
| US-20150250882-A1 | Fatty Acid Acylated Amino Acids for Growth Hormone Delivery | GHRHR, GHSR, GHITM | EPHX2 2404/4885NOD1 4831/4885FAAH 53/4885 |
| US-10905744-B2 | Pharmaceutical formulations for the oral delivery of peptide drugs | SLC30A5, SLC39A11, SLC30A6 | EPHX2 4589/4885NOD1 3431/4885FAAH 4365/4885 |
| US-20200078332-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | EPHX2 4247/4885NOD1 3604/4885FAAH 250/4885 |
| US-20250367295-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | EPHX2 4247/4885NOD1 3604/4885FAAH 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.